Dubbed Bayesian?: Why Adoption Is Slow in Drug Development - 10/27/2025

In last week's blog, I showed that the Frequentist/Bayesian divide is largely philosophical, with practical differences between approaches being limited. Even unique Bayesian methods can often be interpreted in a frequentist manner. Yet, adoption of these methods, dubbed Bayesian, even when appropriately applied, has been slow in drug development. This article explains why.

https://www.linkedin.com/posts/brian-smith-67891a5_in-last-weeks-blog-i-showed-that-the-frequentist-activity-7388596348067028992-PZYl?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAEGlDwBwD0msjnYupwRjlV-PWIsMwwWd3w

Previous
Previous

Why Provisional Knowledge Deserves Careful Communication - 11/3/2025

Next
Next

The Myth of the Tribes: Bridging Bayesian and Frequentist - 10/20/2025